Gilead's Livdelzi Shows Durable ALP Normalization in PBC Phase 3

What happened

Gilead announced interim data from the Phase 3 ASSURE study showing that most PBC patients with ALP 1-1.67xULN achieved sustained composite ALP normalization at 24 months with Livdelzi (seladelpar). This post hoc analysis reinforces Livdelzi's potential as a treatment for primary biliary cholangitis, a niche autoimmune liver disease. However, PBC represents a modest commercial opportunity relative to Gilead's core HIV franchise and the Yeztugo PrEP launch. The data does not alter the near-term investment thesis, which remains centered on Yeztugo's payer access and re-dosing persistence through 2026. The stock's recent 62% rally already prices in HIV durability and Yeztugo upside, leaving limited room for pipeline optionality to drive further multiple expansion.

Implication

Livdelzi's sustained efficacy supports its commercial potential, but investors should not overweight this as a catalyst. The core thesis hinges on Yeztugo execution; PBC revenue, if approved, would be a marginal contributor. The 6-12 month re-assessment window remains tied to Yeztugo access metrics, not PBC data.

Thesis delta

The Livdelzi data confirms pipeline progress but does not shift the thesis. The investment case remains driven by Yeztugo's ramp and HIV cash flow durability. No change to the WAIT rating or entry/exit levels.